MIRZOTAMAB CLEZUTOCLAX

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Investigational

Investigational

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 23:01:24 GMT 2025` Edited by `admin` on `Tue Apr 01 23:01:24 GMT 2025`
Protein Type	MONOCLONAL ANTIBODY CONJUGATE
Protein Sub Type	IGG1
Sequence Origin	HUMAN
Sequence Type	INCOMPLETE
Record UNII	TY49T0B03B
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

MIRZOTAMAB CLEZUTOCLAX

Official Name

English

mirzotamab clezutoclax [INN]

Preferred Name

English

MIRZOTAMAB CLEZUTOCLAX [USAN]

Common Name

English

IMMUNOGLOBULIN G1 (234-ALANINE,235-ALANINE), ANTI-(HUMAN B7 HOMOLOG 3 PROTEIN) (HUMAN MONOCLONAL PR-1651850 .GAMMA.1-CHAIN), DISULFIDE WITH HUMAN MONOCLONAL PR-1651850 .KAPPA.-CHAIN, DIMER, BIS(THIOETHER) WITH 2,6-ANHYDRO-8-(2-(((((2-((3-((4-(6-(8-((2-BE

Common Name

English

Mirzotamab clezutoclax [WHO-DD]

Common Name

English

ABBV-155

Code

English

IMMUNOGLOBULIN G1-KAPPA, ANTI-(HOMO SAPIENS CD276 ANTIGEN (4IG-B7-H3, B7 HOMOLOG 3, COSTIMULATORY MOLECULE)), MONOCLONAL ANTIBODY, CONJUGATED WITH CLEZUTOCLAX, AN INHIBITOR OF BCL-2-LIKE PROTEIN 1 (BCL2-L-1, APOPTOSIS REGULATOR BCL-X); .GAMMA.1 HEAVY CHA

Common Name

English

ABBV155

Code

English

Code System Code Type Description

CAS

2229859-12-3

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

NCI_THESAURUS

C157279

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

INN

11147

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

FDA UNII

TY49T0B03B

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

USAN

JK-93

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

SMS_ID

300000010838

Created by admin on Tue Apr 01 23:01:24 GMT 2025 , Edited by admin on Tue Apr 01 23:01:24 GMT 2025

PRIMARY

From	To
1_23	1_88
1_134	1_194
2_23	2_88
2_134	2_194
3_22	3_96
3_143	3_199
3_260	3_320
3_366	3_424
4_22	4_96
4_143	4_199
4_260	4_320
4_366	4_424
1_214	3_219
2_214	4_219
3_225	4_225
3_228	4_228

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	3_296
N	4_296

Related Record Type Details


					4L7K3H1YON

PARENT -> CONJUGATE

Amount:

Related Record Type Details


					TY49T0B03B

MIRZOTAMAB CLEZUTOCLAX

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_214] [3_219]	SITE_SPECIFIC			MIRZOTAMAB CLEZUTOCLAX CYSTEINE	G592S3RY7N

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL